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GENERAL INTRODUCTION 
Introduction 
There are over 2,200 serotypes of Salmonella, many that have the ability to infect 
both animals and humans. Salmonella is one of the most common foodborne pathogens and 
is responsible for acute gastroenteritis in humans. Because of the increased demand for fresh 
meat and dairy products, international travel, and economic incentive for higher production, 
an increase in foodborne disease is occurring. Additionally, new pathogens are emerging 
while other pathogens are reemerging. To exacerbate the problem of newly emerging, 
reemerging and problematic pathogens that continue to infect animals and humans, many 
species of bacteria are developing resistance mechanisms to evade possible treatment or 
prevention regimes. The development of resistance is especially problematic in human 
medicine if over-use of antibiotics remains unchecked. 
Little research has been done to ascertain the effect(s) antibiotics have on the 
pathogenesis of disease in vivo. Most studies have been conducted in vitro to determine how 
bacteria respond to antimicrobics (i.e. growth or no growth). However, results observed for 
in vivo studies can be very different from results observed for in vitro studies. 
The objectives of this research were twofold. First, an experiment was conducted to 
determine the effect of dose on persistence and shedding of Salmonella heidelberg in 
experimentally inoculated swine. A second study was designed to determine the effect of 
two veterinary antimicrobics on swine experimentally challenged with Salmonella 
heidelberg. 
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Thesis organization 
The thesis contains a general introduction, a literature review of salmonellosis with an 
emphasis on antimicrobic resistance, two manuscripts submitted for publication, a general 
summary, an appendix and acknowledgements. The master of science candidate, Heidi Lea 
Holcomb, is the senior author and principal investigator for the manuscripts. 
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CHAPTER 1. SALMONELLOSIS IN SWINE: A REVIEW OF 
SIGNIFICANT AREAS AFFECTING SALMONELLA AND 
ANTIBIOTIC RESISTANCE 
Salmonella 
General information 
Salmonella was first identified over a century ago by an American veterinarian and 
bacteriologist, Daniel E. Salmon (Guthrie 1992). Salmonellae are Gram-negative rod-shaped 
facultative anaerobes in the family Enterobacteriaceae, which includes other genera such as 
Escherichia, Citrobacter, Proteus, Yersinia, Klebsiella, Shigella, Providencia, Serratia, 
Hafnia, and Erwinia (Ewing 1986). Most salmonellae are motile by peritrichous flagella and 
do not form spores (LeMinor 1984). 
Because salmonellae are primarily intestinal pathogens, they penetrate the intestinal 
mucosa prior to dissemination throughout the host (Lax et al. 1995). An important feature of 
Salmonella is that it is a facultative intracellular pathogen, capable of growing in epithelial 
cells and phagocytic vacuoles of macrophages (Clarke and Gyles 1986). The bacterium's 
mode of survival and growth are important because, once inside the cell, Salmonella appears 
to be more resistant to antibiotics (Collins and Campbell 1982) and resists killing by the 
host's humoral and cellular immune systems. 
Salmonella, like other enterobacteria, produce a variety of virulence factors which 
facilitate colonization in the host. Major virulence factors include cytotoxins, 
lipopolysaccharides, flagella, fimbriae and enterotoxins (Murray 1986). Fimbria and flagella 
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are also virulence factors responsible for attachment and mobility. The other components 
mediate specific events in the host. Together, these factors lead to the production of diarrhea 
and systemic inflammation which can severely damage tissues (Murray 1986). 
Classification 
Salmonellae are typically classified by the Kaufmann-White scheme which utilizes 
antigens present on the cell surface for serological identification (LeMinor 1984). 
Salmonella typhi strains, which are infectious to humans only, contain 0 and H antigens, in 
addition to a capsular virulence antigen, Vi. All three classes of antigens are used in primary 
differentiation of various Salmonella serotypes. 
o (somatic) antigens are a part of the lipopolysaccharide layer of the outer cell wall 
(Guthrie 1992). The arrangement of 0 antigens determine whether salmonellae have a rough 
or smooth colony morphology when grown on agar plates. There are approximately 67 0 
antigens, using letters and numbers to distinguish different "species", or serotypes, of 
Salmonella. There are 8 predominant 0 antigens in pathogenic types of Salmonella (Guthrie 
1992). 
H (flagellar) antigens are components of bacterial flagella (LeMinor 1984). These are 
minor virulence factors for most Salmonella serotypes. Vi (capsular) antigens comprise 
capsule and envelope surrounding a bacterium (Guthrie 1992). These antigens are important 
virulence factors in Salmonella typhi infections. 
Most investigators in the field refer to serotype as the designation of species for 
reporting purposes, even though there is technically only one Salmonella species (LeMinor 
5 
1984). Approximately 2,200 serotypes of Salmonella have been identified using the 
Kaufmann-White scheme (LeMinor 1984). From humans or animals, however, less than 50 
serotypes are frequently associated with disease (Clarke and Gyles 1986). 
Bacteriology 
Growth and metabolism 
The simplest way to identify Salmonella is based on the bacteria's metabolic 
processes (LeMinor 1984). Salmonellae can grow aerobically or as facultative anaerobes at 
8-45°C. An incubation temperature of 37°C is recommended (Ewing 1986). Aerobic 
conditions are thought to increase growth rate (Guthrie 1992). Most salmonellae can be 
killed at temperatures >65°C and are resistant to drying, making survival in dust possible 
(Guthrie 1992). 
A majority of enterobacteria utilize citrate as the sole source of carbon (Guthrie 
1992). Salmonellae produce acid and gas during fermentation of glucose and mannose. 
Most, however, do not ferment lactose or sucrose. During fermentation of glucose, hydrogen 
sulfide is usually produced (LeMinor 1984). While most salmonellae produce hydrogen 
sulfide, exceptions are noted (Poppe et a1. 1995). 
Culture methods 
Use of enrichment media facilitates the recovery of salmonellae from a sample. A 
variety of media can be utilized. Pre-enrichment broths may be used initially to help bacteria 
recover from the stress of movement into a new environment and losses due to cell death 
(Guthrie 1992). Examples include peptone water or tryptone broth. Most often, selective 
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enrichment media is used to stimulate growth of Salmonella and inhibit growth of unwanted 
bacteria. Tetrathionate, selenite and Gram-negative (GN) broths and Rappaport-Vassialidis 
medium all support growth of Salmonella and inhibit growth of other bacteria (Ewing 1986, 
Vassiliadis 1983). 
Plating onto solid media makes it easier to identify only salmonellae and is 
subsequent to culture in liquid media. Bismuth Sulfite agar has been reported to be the best 
at inhibiting most other enterobacteria (Guthrie 1992). Other agars include Brilliant Green, 
Salmonella-Shigella, and xylose-:-Iysine-tergitol 4 (XLT4; a hydrogen sulfide indicator; Dusch 
and Altwegg 1995). Less selective agars are MacConkey, hektoen enteric, desoxycholate, 
and eosin-methylene blue (Guthrie 1992). 
Identification 
After selection of presumptive positive colonies from agar plates, suspect colonies are 
inoculated into various media to determine biotype. These include triple sugar iron agar, 
lysine iron agar, urease, and indole. Further identification utilizes somatic and flagellar 
antigens as mentioned previously (LeMinor 1984). Additional techniques for classification 
and analysis of significant Salmonella serotypes include phage typing, antibiotic 
susceptibility patterns and plasmid fingerprinting (Vatopoulos et al. 1994). 
Epidemiology 
While typhoid fever (a disease associated with Salmonella typhi) has decreased 
dramatically in the past 50 years, all other salmonelloses have increased (Cohen and Tauxe 
1986). Salmonellosis now ranks as the fourth most infectious disease in the United States 
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(Anonymous 1996b). The predominant serotypes recovered from humans are S. enteriditis, 
S. typhimurium, S. newport and S. heidelberg (Anonymous 1996a). Order of recovery may 
vary slightly between years. 
Host adapted strains include S. typhi in humans, S. choleraesuis in swine, S. dublin in 
cattle and S. pullorum in poultry (Schwartz 1990). These strains are host specific and rarely 
infect other hosts. However, following infection in humans with S. choleraesuis, severe 
disease and death may result (Weissbluth et al. 1981). Non-host adapted strains include S. 
typhimurium, S. enteriditis, and S. heidelberg, which comprise most Salmonella serotypes 
found today in both humans and animals (Ferris and Miller 1996). 
Salmonellae are ubiquitous in the environment and have been recovered from nearly 
all vertebrates (Taylor and McCoy 1969). Outbreaks occur most frequently during the 
summer months and may be observed in late fall (Hook 1990). Human infections are usually 
foodbome and frequently cause gastroenteritis. Those most affected by salmonellosis are 
usually less than 5 years of age (Hook 1990), elderly (Levine et al. 1991), 
immunocompromised (Levine et al. 1991) or hospitalized (Baine et al. 1973). Economic 
losses due to salmonellosis in the United States have been estimated to be $1.1 billion 
(Tauxe 1991) or as high as $4 billion for 3 million human cases (Todd 1989). 
Pathogenesis in swine 
Salmonellosis is a major bacterial disease of swine, second to swine dysentery 
(Schwartz 1990). Salmonellosis in swine results in tremendous economic losses in the pork 
industry (Roof et al. 1992). Estimates range from $28 million per year in Iowa to $100 
8 
million in the United States (Schwartz 1990). 
The predominant serotypes isolated from swine are S. derby, S. choleraesuis, and S. 
typhimurium-copenhagen (Ferris and Miller 1996). In Iowa, S. choleraesuis infections pose 
the biggest problem to producers, comprising >95% of the porcine salmonellosis cases 
(Schwartz 1990). Infection following exposure to S. choleraesuis is characterized as a 
septicemia with destruction ofthe pulmonary tissues. Its primary mode of transmission, like 
most Salmonella, is fecal-oral (Heard and Linton 1966) or respiratory (Wathes et al. 1988, 
Tannock and Smith 1971, Hardman et al. 1991). Salmonella typhimurium, on the other hand, 
is a gastroenteric pathogen causing severe diarrhea and wasting in swine. Clinical signs 
associated with salmonellosis in swine are fever, diarrhea, lethargy and dyspnea (Schwartz 
1990). 
Five main disease states have been associated with Salmonella infections: 
enterocolitis, as observed following infection with S. typhimurium, where salmonellae are 
detec.ted in feces but not blood; bacteremia, as observed following infection with S. 
choleraesuis, isolating organisms from the blood but not the feces; localized infections 
following infection from a variety of salmonellae; development of a carrier state in many 
animals; and enteric fever (in humans only) as observed following infection with Salmonella 
typhi (Hook 1990). 
The carrier state has been shown to be important in the survival and persistence of 
Salmonella in the environment (Gray et al. 1995). Following infection with S. choleraesuis, 
immune suppression has been observed in carrier pigs, compromising the host (Gray et al. 
1996). Penmates can also be compromised. Gray et al. (1995) showed that naive pigs 
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exposed topigs shedding 2.6 logs/gram feces will become infected and show clinical signs of 
disease within one day after commingling. Salmonella was recovered from the naive pigs up 
to 9 weeks after exposure. Bacteria can proliferate in the gastrointestinal tract of carrier pigs 
after they have been stressed (Morgan et al. 1987, Williams and Newell 1970). Carrier 
animals are thought to be the main source of Salmonella infections in other animals or 
humans (Wray and Sojka 1977). 
Pathological observations indicate the development of lesions, enlarged lymph nodes, 
and hemorrhagic and inflammed intestinal epithelium (Schwartz 1990). Inflammation leads 
to malabsorption and fluid loss (Clarke and Gyles 1986). With S. choleraesuis infections, 
lungs can be consolidated, hemorrhagic and edematous (Schwartz 1990). A characteristic 
lesion is the paratyphoid nodule on the liver (Wilcock and Schwartz 1992). Severe tissue 
damage and necrosis, particularly in the intestine (Clarke and Gyles 1986), can result from 
toxins produced by Salmonella, all of which influence the host's immune response. 
Antibiotic Therapy 
Background 
Antibiotics have been used to treat bacterial infections in animals and humans for 
decades since the inception of penicillin (Martel and Coudert 1993). Their use has expanded 
to include prevention of disease and growth promotion in animals (Wray et al. 1993), which 
results in a major economic advantage for producers. Since their inception, antibiotics have 
been extremely effective. Scientific research is continually expanding to produce new 
antibiotics to combat present and emerging bacterial pathogens. 
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Classes 
There are many classes of antibiotics that are utilized in human and animal medicine. 
Some are efficacious in both practices, differing in the concentration or route of inoculation. 
This section will focus on those antimicrobics that apply to the field of veterinary medicine. 
Most antibiotics can be classified by their general action against bacteria. Penicillins, 
aminoglycosides, cephalosporins and cephamycins, quinolones and miscellaneous 
antimicrobial agents like nitrofurans are known to be bactericidal in nature (Anonymous 
1991). They are capable of destroying bacteria in a host. Penicillins, cephalosporins and 
cephamycins (p-Iactam antibiotics) act by preventing bacterial cell wall synthesis by 
inhibiting transpeptidase that forms cross-bridges in Gram-positive and Gram-negative 
organisms. They are most effective during bacterial log phase of growth, before the cell wall 
is fully synthesized. 
Aminoglycosides are broad spectrum antibiotics that bind to membrane associated 
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ribosomes. They inhibit protein synthesis and eventually disrupt the cell wall (Guthrie 1992). 
Various aminoglycosides can be very effective when used in conjunction with p-Iactams. 
Examples include streptomycin, which is effective against Gram-negative bacteria, and 
kanamycin and neomycin, which are effective against both Gram-negative and Gram-positive 
bacteria. Aminoglycosides are not currently approved for use in food-producing animals. 
Quinolones are a relatively new class of antimicrobic. They are synthetic, broad-
spectrum antibiotics which have been efficacious in human medicine and have expanded to 
be used in animal medicine in the last 10 years. Their primary mode of action is inhibition of 
DNA gyrase, or topoisomerase II, which leads to improper supercoiling and cell lysis 
11 
(Wolfson et al. 1989). Quinolones are well accepted for treatment of a variety of bacterial 
infections. Naladixic acid has predominantly been used in humans for treatment of urinary 
tract infections. Quinolones are noted for their ability to inhibit intracellular pathogens, such 
as Salmonella (Guay 1992). They are favored because of their route of administration, wide 
tissue distribution and relative safety. 
Nitrofurans are another broad spectrum, synthetic group of antibiotics, primarily used 
in animal medicine, especially swine health. They inhibit an enzyme required for the 
initiation of translation (Anonymous 1991). 
Tetracylines, chloramphenicol and congeners, macrolides, lincosamides and 
miscellaneous antimicrobics such as bacitracin, vancomycin, novobiocin, tiamulin, 
sulfonamides and sulfonamide combinations are all classified as being bacteriostatic. 
Tetracyclines bind to ribosomes and thus inhibit protein synthesis. They are used widely to 
treat disease in humans and animals. In addition to treatment, they are used as feed additives 
to enhance growth in food producing animals (DuPont and Steele 1987). 
Chloramphenicol is a broad spectrum antimicrobic used in treating local and systemic 
infections in animals and humans. However, because ofthe possibility of sporadic 
hypersensitivity reactions, use is limited to non-food producing animals. It is very 
effacacious against Gram-positive and Gram-negative bacteria implicated in 
meningoencephalitis, otitis, abscesses or respiratory infections (Anonymous 1991). 
Another group of antimicrobics that interferes with protein synthesis is the macrolide 
class of antibiotics, which include tylosin and erythromycin. They are widely distributed in 
tissues after administration and control pneumonia, enteritis, metritis and urinary tract 
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infections (Anonymous 1991). 
Gram-positive cocci are inhibited by lincosamides which act by altering ribosomal 
subunits (Guthrie 1992). Most other Gram-positive bacteria are inhibited by bacitracin and 
vancomycin which act against the cell wall. Novobiocin, frequently used to treat bovine 
mastitis, and tiamulin are also effective against Gram-positive bacteria found in veterinary 
medicine (Anonymous 1991). 
Sulfonamides are widely used antimicrobials, especially in feed (DuPont and Steele 
1987). They have a broad spectrum of activity and are relatively inexpensive. Urinary tract 
and intestinal infections are controlled by the use of sulfonamides. Because of their 
similarity to para-amino benzoic acid (PABA), they are able to inhibit a step in the synthesis 
of folic acid, leading to suppression of nucleic acid synthesis. Sulfonamides are more 
effective when combined with trimethoprim, which inhibits dihydrofolate reductase. Used 
alone both antibiotics are bacteriostatic but can be bactericidal when combined (Bushby 
1980). 
It has been observed that antibiotics can have an effect on the immune system as well 
as the bacteria causing the infection. Some antibiotics actually suppress the immune system 
during in vitro testing and include tetracycline, ampicillin and erythromycin (Van Vlem et al. 
1996). More testing in vivo is recommended to augment the limited information which is 
available regarding immune response to antibiotic treatment in both animals and humans 
(Van Vlem et al. 1996). 
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Problems with antibiotic use 
Antimicrobics are very effective in reducing numbers of bacteria in a host. They 
must, however, be used properly to ensure efficacy. If not used correctly the effects can be 
detrimental. Complications such as reinfection or long term carriage, drug induced toxicity, 
or a"development of resistance by the pathogen often occur following improper use, (Hook 
1990). Problems arise when the antibiotic is not used according to specified instructions, 
which includes duration of treatment, route of administration and concentration of antibiotic. 
Most research has focused on treatment of human clinical illnesses with antibiotics. 
Few studies are available on effectiveness of antibiotics following animal bacterial infections. 
There is a general agreement among researchers that more work needs to be done in the area 
of treatment of veterinary pathogens (Hook 1990). Much of the research on antibiotic 
therapy has been done in vitro. Conclusions from in vitro studies are not thought to be 
indicative of in vivo situations (Stevens et al. 1995). 
It is possible to observe no change in clinical signs of infection after a presumably 
effective antibiotic has been administered. Evangelisti et al. (1975) saw no response to 
treatment with oxytetracycline in swine inoculated with S. typhimurium. Jacks et al. (1988) 
observed similar results following use of efrotomycin in swine experimentally infected with 
S. typhimurium. In both studies, no differences were observed between treated and untreated 
groups. 
A study involving pigs from a Salmonella-infected farm indicated no decrease in 
numbers of positive pigs following treatment with enrofloxacin (Dahl et al. 1996). Willson 
and Osborne (1985) observed no treatment effect following use of oxytetracycline, long-
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acting oxytetracycline, or spiromycin (in feed) in swine chronically infected with 
Actinobacillus pleuropneumonia. Penicillin, ampicillin or ceftiofur sodium all failed to 
control a Streptococcus suis infection (Amass et al. 1996). 
Failure to reduce environmental levels of the bacteria after treatment can have a 
detrimental effect on animals left in contact with shedding animals. Hunnemann et al. (1994) 
demonstrated transmission of a non-responsive A. pleuropneumonia (AP) to naive swine. 
Oxytetracycline in the feed was not able to control AP infection, nor prevent newly 
introduced pigs from acquiring the bacteria. This contributes to a cumulative decline in the 
health of animals. 
Carrier animals may also be fostered during antibiotic treatment (Clarke and Gyles 
1986). If the bacterium is not eliminated, it may now survive in spite of the use of an 
antimicrobic and persist as a latent infection within the host. Treatment can also at times 
cause persistent shedding ofthe bacteria (Hook 1990). Aserkoff and Bennett (1969) have 
found that some antibiotics actually prolong excretion of bacteria, especially Salmonella, in 
humans. 
Another result from antibiotic use may be the induction of a more severe disease state 
for which the antibiotic was given. This usually arises because some antibiotics also destroy 
microbial intestinal flora in addition to the intended bacterial pathogen (Tauxe 1991). 
Destruction of natural flora can give rise to more serious infections. Reports indicate that 
antibiotics promote Salmonella infections, primarily in humans (Holmberg et al. 1984, Spika 
et al. 1987). Amass et al. (1996) found that after treatment failed to clear a Streptococcus 
suis infection, more severe clinical signs were evident following use of high doses of 
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penicillin. Additionally, resistant bacteria were observed after treatment. 
The development of resistance has become a prominent issue in the application of 
antimicrobics (Cohen 1992, Perez-Trallero and Zigorraga 1995). Bacteria may be able to 
survive the selective pressure that accompanies antibiotic usage. Those that survive can 
become resistant to that antibiotic. Evangelisti et al. (1975) observed resistant S. 
typhimurium in chickens after treatment with oxytetracycline in feed. Smith and Tucker 
(1978) did not observe any decrease in infection after treatment with neomycin in chickens 
infected with Salmonella. Additionally, they noted the development of neomycin resistant E. 
coli following treatment. Ling et al. (1992) also observed the emergence of resistant bacteria 
after treating a previously sensitive strain of S. typhi with cotrimoxazole. 
Antibiotic resistant organisms have been observed after use of medicated feed, which 
is intended for promotion of growth (DuPont and Steele 1987). Resistance develops due to 
the long-term use of medicated feed containing low concentrations of antibiotics (Cherubin 
1984). 
Mechanisms of resistance 
Antimicrobic resistance was first observed in 1940, with coli-typhoid bacteria that 
produced penicillinase and were resistant to penicillin (Abraham and Chain). Throughout 
the era of antibiotic therapy, bacteria have become successful at surviving the destructive 
effects of antimicrobics. A review of the literature suggests a rapid rise in the development 
of resistance since the 1960's. Antibiotics are no longer considered a cure-all. Bacteria have 
developed ways to survive the onslaught of antimicrobic use and are developing resistance to 
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one or more antibiotics. 
Resistance to any of the previously mentioned antibiotics can develop by altering 
target sites, membrane permeability or enzyme activity (Silva 1996). Enzymatic inhibition is 
the most common mode of resistance. Resistance that occurs following use of penicillins, 
aminoglycosides, cephalosporins, and chloramphenicols is based on the increase in 
production of an inactivating enzyme, p-Iactamase, which cleaves p-Iactam rings present in 
all of these antibiotics (Anonymous 1991). Staphylococci are able to develop resistance 
relatively quickly using this mode. Other bacteria capable of producing p-lactamase are 
E.coli, Haemophilus, Klebsiella, Pastuerella, Proteus, Pseudomonas and Salmonella spp. 
Enterobacteria can also undergo chemical modifications to prevent aminoglycosides 
from acting on ribosomal subunits (Silva 1996). Additionally, they can produce an enzyme, 
chloramphenicol acetyl transferase, to inhibit chloramphenicol. Some bacteria, namely 
Shigella and Staphylococcus aureus, abundantly produce dihydrofolate reductase to inhibit 
actions of trimethoprim. 
Certain microorganisms are capable of developing resistance by altering penicillin 
binding proteins to negate the effects penicillins and cephalosporins have on peptidoglycan. 
Macrolide, lincosamide and aminoglycoside resistance may develop as a result of 
methylation of a ribosomal subunit (Silva 1996). Bacteria may develop resistance to 
sulfonamides by using alternate metabolic paths or increasing synthesis of para-amino 
benzoic acid (PABA). 
Chromosomal mediated resistance is thought to develop slowly, mediated by a slow 
rate of mutation. Quinolone resistance is chromosomally mediated and develops from 
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mutations in gyrase genes over a period oftime (Wolfson et al. 1989). This slower 
acquisition of resistance prolongs effectiveness of treatment. 
Some microorganisms, like Pseudomonas aeruginosa, simply have impermeable cell 
walls (narrow porins) that will not allow the entry of antibiotics, such as penicillins, 
cephalosporins, aminoglycosides, tetracycline and chloramphenicol (Jacoby 1986, Trias and 
Nikaido 1990). Carbenicillins seem to have difficulty entering cells because of its largely 
hydrophobic nature and negative charge (Hancock 1997). Some antibiotics, like macrolides, 
are more effective against Gram-:-positive organisms because they are unable to penetrate the 
outer membrane of Gram-negatives (Anonymous 1991). 
Types of resistance 
There are many types of bacterial resistance, including natural, acquired, 
chromosomal, plasmid, transpositional, phenotypic, microbiological, and clinical resistance 
(Anonymous 1991). The most important to the animal health field are acquired resistance 
utilizing plasmids and chromosomes (Perez-Trallero and Zigorraga 1995). 
Chromosomal resistance 
Chromosomal resistance occurs by a single step or spontaneous mutation that will in 
tum modify a target to decrease susceptibility to the antibiotic (Jacoby and Archer 1991). 
This type of resistance is not common and can only be passed on to progeny, not to other 
bacteria. Quinolone resistance is commonly thought to be chromosomally encoded (Guay 
1992). 
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Plasmid resistance 
Plasmids are mobile, extrachromosomal factors that can carry genes for resistance or 
virulence (Silva 1996). Plasmids that carry genes for resistance are also called R factors 
(Guthrie 1992). These can be passed on, not only to progeny, but also to other species of 
bacteria. Plasmid mediated resistance is more common than chromosomal resistance and is 
typical for p-Iactam, amino glycoside, and chloramphenicol resistance. Their presence may 
encourage resistance to develop and their withdrawal may enable a reversion to 
susceptibility. 
Plasmid transfer can occur three ways: transformation (occurs in few bacteria), 
transduction (phage-assisted transfer) and the most sophisticated transfer, conjugation. 
Conjugation occurs between donors and recipients, requiring a sex pilus (Anonymous 1991). 
It occurs more frequently in Gram-negative bacteria than Gram-positive bacteria. 
Conjugation is unique in that resistance, even multiple resistance, can be transferred to 
different species of bacteria in one step. Many bacteria can be recipients of resistance. 
Salmonella bacteria are most often found to carry resistance plasmids (Blackburn et al. 1984, 
Poppe et al. 1995). 
Enteric pathogens may have the ability to acquire R factors from other gut flora 
(Linton et al. 1981). If exposure occurs, animals or humans may aquire R factors from 
various sources. This suggests the potential for transfer of resistance between human and 
animals but is difficult to assess behavior in either host prior to acquisition of resistance. 
This type of transfer has been demonstrated in mice (Smith and Tucker 1978) and may lead 
to development of additional resistance (Aserkoff and Bennett 1969). 
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Transpositional resistance 
A less prominent type of resistance occurs on transposons or mobile genetic elements. 
Transposons are gene sequences that can migrate between plasmids, chromosomes, or 
bacteriophages (Silva 1991). They frequently contain genes encoding resistance and can 
facilitate the spread of resistance (Jacoby and Archer 1991). 
Problems with antibiotic resistant bacteria 
Current situation 
Bacterial resistance has become an important problem in treating human as well as 
animal infections. Pharmaceutical industries are trying to keep up with demand for novel, 
more efficacious antimicrobics to treat infections now caused by resistant bacteria. The 
general usefulness of antimicrobics has declined (Linton 1977). It seems that more bacteria 
are developing resistance to even novel antibiotics than before. Clearly, there is an 
association between antibiotic use and the development of resistant bacteria (Anonymous 
1997, McCaig and Hughes 1995, Linton 1977). 
Currently, the majority of antibiotics used in human medicine are for therapy, while 
most used in animal medicine are for prophylactic treatment and growth promotion (DuPont 
and Steele 1987). Half of all antibiotics used in the United States are for food producing 
animals (Lee et al. 1993). In the United States, 55-60% of tetracycline and penicillin is used 
in feed at subtherapuetic levels (Anonymous 1989a, Bennett 1980). In this way, large 
numbers of animals are exposed to antibiotics, increasing the rate at which resistance may 
develop and persist (Cohen 1992). 
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The majority of resistance observed in human health is a result of overuse of 
antibiotics directly in humans (Norrby 1996), not from transfer from animals or meat 
products. Animal feed has been improperly blamed for the transfer of resistance to humans 
after consumption of meat products from animals fed medicated feed (Cherub in 1984). 
Problems 
Progress in drug development has been slow. It has been approximately 15 years 
since the last class of antimicrobics has been discovered (Spratt 1996). In Europe, bacteria 
have already developed resistance to this latest group of antimicrobics, the fluoroquinolones 
(Kresken et al. 1994). Development of resistance hinders treatment as resistant bacteria are 
more difficult, if not impossible, to treat than susceptible ones. 
Resistance can also develop in animals from low-level, long-term use in feedstuffs 
(DuPont and Steele 1987) which may select for resistant bacteria (Linton 1977). Resistance 
can be passed from animal to animal, animal to human, and human to human (Levy 1987). 
Olsvik et al. (1985) observed transmission of a resistant strain of S. typhimurium from 
animals to farm workers. Animals with resistant bacteria may contribute to resistance 
observed in humans (Ryder et al. 1980) and can cause serious illnesses (Holmberg et al. 
1984). It is also likely that transfer of resistance from human to animal also occurs. In third 
world countries, human wastewater has been implicated in introducing drug resistant 
Salmonella to shellfish and fish (Anonymous 1989b). These modes of transfer clearly pose a 
threat to animals or humans in contact with the contaminated individual or animals which 
carry the resistant bacteria. 
Problems may arise in treatment of patients with infections due to resistant bacteria. 
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Higher health care costs due to more hospitalizations may result from the increase in 
antibiotic use (Sundlof and Cooper 1996). Resistance may also lead to higher death rates in 
humans (Holmberg et al. 1984). High morbidity in Kenya was observed and was attributed 
to antibiotic resistant bacteria which were present in large numbers of immunocompromised 
patients (Kariuki et al. 1996). 
Methods of control 
Many methods to control the development of resistant bacteria have been proposed. 
Reducing antimicrobic levels in animal feed has been suggested as a solution to decreasing 
the ability for bacteria to develop resistance in the animal populations (DuPont and Steele 
1987). The removal of selective pressure from antibiotics in feed is believed to decrease the 
numbers of resistant organisms (Levy 1987). However, this area is controversial. In the 
United Kingdom, a decrease in the amount of antibiotics used in feed has not had an impact 
. 
on the reduction of resistant organisms (DuPont and Steele 1987). The reason for these 
differences is unclear. 
As antibiotic use has increased, so has the need for ways to observe the impact on 
animals, food and the environment (Martel and Coudert 1993). Surveillance is an important 
tool to identify areas of concern regarding increased development of resistant 
microorganisms. Facilities in England and Wales have monitored Salmonella sensitivity in 
animals since 1970 (Wray et al. 1993), and susceptibility testing is common in many 
laboratories (Blackburn et al. 1984, Lee et al. 1993, Ryder et al. 1980). Increases in 
surveillance have been requested, especially on farms and in hospitals, to observe movement 
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of resistance plasmids and track trends in resistance patterns (Cherub in 1984, Cohen 1992, 
DuPont and Steele 1987). 
It has been proposed that it may be effective to use antibiotics wisely by choosing 
those that have limited means of initiating resistance (Mortensen et al. 1996). Additionally, 
prudent and restrained use of antibiotics in humans and animals is desired for the prevention 
and treatment of bacterial infections (Goldmann et al. 1996, Holmberg et al. 1984, Cohen and 
Tauxe 1986, Cherubin 1984). Pharmaceutical companies have advocated short-term, high 
dose administration of antibiotics in the prevention and control of drug resistant bacteria 
(Sundlof and Cooper 1996). Inappropriate use is discouraged and treatment lengths should 
be carefully monitored and reduced if possible (Cohen 1992). In addition to decreasing 
indiscriminate use by doctors, patients also playa significant role in decreasing the use of 
antibiotics (McCaig and Hughes 1995). 
Development of novel classes of antibiotics are warranted. Many studies are being 
conducted, targeting specific areas of bacterial structure for development of new 
antimicrobics (Vaara 1996). Chopra et al. (1996) introduce the idea of using analogs of past 
antibiotics as a new way to combat resistant microbes. Enzyme inhibitors could be 
incorporated with antibiotics to prevent degradation by enzymes produced by the bacteria 
(Chopra et al. 1996). Novel methods are desired to keep up with the development of resistant 
organisms. 
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Future Direction 
Emphasis for on-farm control of salmonellosis in animals is warranted. Since 
Salmonella contamination is almost impossible to prevent and salmonellosis is very difficult 
to treat, an understanding of the pathogenesis and transmission of the organism is imperitive. 
Antibiotic therapy is becoming limited in its usefulness. Prophylactic use compounds 
the problem by enhancing the development of resistant bacteria. Limiting use of antibiotics 
in humans and animals has been desired for years. Development of new antibiotics, even if 
beneficial for only a short time, is desirable. However, long term control of the problem 
targets development of vaccines and enhancing the immune response of the host to control 
infectious diseases. 
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CHAPTER 2. EFFECT OF DOSE ON PERSISTENCE AND SHEDDING 
OF SALMONELLA HEIDELBERG IN SWINE 
A paper submitted to the Journal of Food Protection 
Heidi L. HolcombA,B and Paula J. Fedorka-CrayB* 
ABSTRACT 
The effect of inoculation dose on shedding of Salmonella heidelberg in swine was 
studied. Forty-five Salmonella-free pigs were placed into 4 groups. Groups 1,2 and 3 
(n=12/group) received 103, 106, or 109 CFU Salmonella heidelberg, respectively, intranasally 
at 6 weeks of age. Group 4 (n=9) served as controls. Pigs (4/group and 1 control) were 
necropsied at 2, 4, and 6 weeks post-challenge (PC). Tonsil and nasal swabs, rectal loops 
(TNR) and clinical signs were monitored throughout the study. Following challenge, only a 
mild to moderate cough was observed. On day 5 (D5) PC, 5/33 (15.2%) swabs and loops 
were positive for Group 1 compared to 22/36 (61.1%) for Group 2 and 31133 (93.9%) for 
Group 3. Peak shedding levels occurred on D7 for Groups 1 and 3 (2.95 and 6.17 logs, 
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respectively), while Group 2 levels peaked on D 1 0 ( 4.31 logs). Shedding ceased in Group 1 
by D36 PC. More tissues were positive from Group 3 than any other group at the 4 and 6 
week necropsies. For all groups, the tissue colonized with the highest numbers of Salmonella 
was the ileocolic junction. These data indicate that infection with S. heidelberg does not 
result in apparent clinical disease, regardless of dose. However, a dose dependent correlation 
was observed with respect to shedding and number of positive tissues. 
Key words: Salmonella heidelberg, foodbome disease, swine 
INTRODUCTION 
Salmonella heidelberg is a non-host adapted serotype of swine, the fourth most 
frequently isolated Salmonella serotype from swine and humans (11, 24). It has also been 
recovered from cattle (21) and is a predominant serotype found in poultry (6, 11,20). 
Salmonella heidelberg causes a wide variety of infections in humans, including 
gastroenteritis (7). Septicemia and meningitis with up to 18% case mortality have been 
observed in infants (1) along with atypical associations in adults like false appendicitis (27), 
joint infection (17) and abscesses due to bacteremia (16,25). 
Foodbome salmonellosis has been associated with consumption of meat and meat 
products, including pork or pork products, in addition to eggs (4). Since swine, cattle, 
poultry and seafood have been implicated in carriage of foodbome pathogens (2), it is likely 
that most foodbome disease is a result of ingestion of contaminated products. Human to 
human, animal to human, and contact with contaminated non-food sources are other means of 
initiating foodbome-related illnesses. 
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Much is known about host-adapted strains of Salmonella, such as S. dublin in cattle 
(5) and S. choleraesuis in swine (12, 13, 14,23,26). However, other than S. typhimurium, 
most non-host adapted strains have received little attention regarding their pathogenesis. 
Various aspects regarding the pathogenesis, carrier state, or transmission of S. heidelberg are 
relatively unknown. 
Anecdotal reports implicate S. heidelberg in on-farm subclinical and clinical disease 
in swine. However, the extent of infection is unknown. Only one published report is 
available regarding experimental S. heidelberg infection in swine (22). Reed et al. (22) 
observed clinical manifestations resembling infection with enterotoxigenic E. coli following 
challenge with 1010 CFU S. heidelberg. This differs from clinical disease following 
challenge with S. typhimurium (8, 10,30) or S. choleraesuis (12, 14). 
The objective of this study was to determine the effect of dose on persistence and 
shedding of S. heidelberg infection in swine. The immune response was also measured. 
MATERIALS AND METHODS 
Bacterial strains and challenge culture Salmonella heidelberg (isolated from swine) was 
obtained from the National Veterinary Services Laboratories, Ames, Iowa, and assigned 
number 25K5-7. Challenge cultures were prepared by inoculating 5 ml Luria Bertani (LB) 
broth with ~ 100 III of a frozen (-70°C) stock culture and incubating overnight at 37°C and 
150 rpm. A 1 % inoculum from the overnight culture was transferred into 250 ml LB and 
grown for approximately 3.5 hours at 37°C and 150 rpm. The culture was centrifuged, the 
pellet was resuspended in 30 ml 0.1 M phosphate buffered saline (PBS, pH 7.2) and adjusted 
34 
to a final concentration of 1.01 x 109 CFU/ml in PBS (OD600=--1.00). The 106 CFU/ml 
culture was made by diluting the 109 culture 1: 1 000 in PBS. A subsequent dilution (1: 1 000) 
of the 106 culture was used as the 103 culture. Final concentrations were confirmed by plate 
counts on trypticase soy agar plates. 
Swine Source sows were cultured on the farm for Salmonella spp. pre- and post-farrowing. 
Forty-five 10-14 day old pigs were weaned from Salmonella culture-negative swine and 
transported to isolation facilities at the National Animal Disease Center. Pigs were raised in 
isolation as described by Fedork.a-Cray et al. (9). Prior to challenge, fecal pools and 
individual rectal loops were obtained from pigs and cultured for Salmonella. 
Experimental procedure At 6.5 weeks of age, 45 Salmonella culture-negative pigs were 
randomly assigned to 4 groups. Control pigs were housed in separate isolation facilities. 
Within each building, all animals were housed in pens of similar size. Groups 1, 2, and 3 
(n=12/group) were challenged at 6.5 weeks of age (day 0) intranasally, with 1 ml (0.5 ml in 
each nostril dropwise, alternating nostrils) of S. heidelberg at a concentration of 103, 106 and 
109 CFU/ml, respectively. Group 4 pigs (n=9) served as uninoculated controls. 
Pigs were observed for clinical signs of disease post-challenge (PC). Rectal 
temperatures were taken daily from all pigs for 1 week and then once a week for 5 weeks. 
Tonsil and nasal swabs and rectal loops (TNR) were obtained from pigs for bacteriologic 
culture on days 1 through 7, 15,22,29,36, and 43 PC. Fecal pools were obtained for 
bacteriologic culture on days 3, 7, 10, 15,22,29,36 and 43 PC by mixing fresh feces from 
the entire pen and randomly collecting 109 of feces from the mixed pile. Blood samples 
were obtained for serum on days -1, 13,27 and 41 PC. 
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Four pigs from Groups 1,2 and 3 and 1 pig from Group 4 were necropsied at 2, 4 and 
6 weeks PC. Tissues were obtained using aseptic technique and included tonsil, mandibular 
lymph node (MLN), bronchiole lymph node (BLN), lung, liver, spleen, colonic lymph node 
(CLN), colon, ileocolic lymph node (ICLN), ileocolic junction (ICl), cecal contents (Cec· 
Cont), cecum, middle ileum (Mid II), and stomach wall (SW). 
Bacteriologic examinations Fecal pools, TNR samples and tissues were placed into 
tetrathionate broth (Difco Laboratories, Inc., Detroit, MI) and incubated for 48 h at 37°C. 
Samples were transfered to Rappaport RlO medium (28), incubated for 24 h at 37°C and then 
streaked onto xylose-Iysine-Tergitol-4 (XL T4) agar plates (Difco). All XLT4 plates were 
incubated for 24 h at 37°C. Suspect colonies were inoculated into triple sugar iron agar 
(Difco) and lysine iron agar (Difco) slants for biochemical confirmation. All presumptive 
positive colonies were serogrouped by agglutination with Salmonella 0 antiserum Group B 
(Difco). At least one isolate from each pig was sent to the National Veterinary Services 
Laboratories for serotyping. 
Quantitative bacteriologic culture of fecal pools, tonsil, lung, ICJ, ICLN and Cec 
Cont were performed as previously described using the most probable number method (31). 
Results are recorded as mean values from each group at each necropsy. 
Antigen preparation For lymphocyte blastogenesis assays, S. heidelberg lipopolysaccharide 
(LPS) antigen was prepared according to the method described by Morrison and Leive (18), 
lyophilized, and stored at -70°C until use. For ELISA assays, heat extract S. heidelberg 
antigen was made as described by Gray et al. (12). Briefly, frozen stock culture was scraped 
with a sterile swab and placed into LB broth. The culture was incubated at 37° C and 220 
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rpm for 16 h, centrifuged at 15,000 x g for 10 min and the supernatant was discarded. The 
pellet was resuspended in 1110 volume ofO.lM PBS and placed in an erlenmeyer flask. The 
resuspended cells were heated in a 60°C water bath for 1 h with periodic gentle agitation, 
then centrifuged at 19,000 x g for 6 min. The supernatant was decanted, filtered through a 
Millex-GV 0.22 ~m filter (Millex-GV, Millipore, Bedford, MA) and stored at -20°C until 
use. Protein concentration (~g/ml) was determined as described by Bradford (3) using 
bovine serum albumin as the standard. 
Enzyme linked immunosorbent assay The ELISA assay was performed as described by 
Gray et al. (12) in 96-well microtitration plates (Immulon, Dynatech Laboratories, Inc., 
Chantilly, V A). Antigen concentration was adjusted to 4 ].lg S. heidelberg heat extract 
protein per well. Goat anti-swine peroxidase conjugated antibody (Kirkegaard & Perry 
Laboratories, Inc., Gaithersburg, MD) was used at a 1 :2000 dilution in diluent buffer. 
Following the addition of substrate (one component of3,3'5,5 tetramethylbenzidine 
micro.well substrate; Kirkegaard & Perry), the reaction was stopped after 10 minutes. Plates 
were read using a Dynatech MR 7000 with a reference wavelength of 41 0 nm and a test 
wavelength of 450 nm. Group optical densities were determined by taking the mean 
experimental value/group minus the mean control value/group at each necropsy. 
Blastogenesis assay Blastogenesis assays were performed on days -1, 13,27 and 41 PC. 
Ten ml of heparinized blood was collected from each pig and diluted in 10 ml Hank's 
balanced salt solution (HBSS) without calcium or magnesium, then layered over Ficoll-
Paque (Pharmacia, Uppsala, Sweden) and centrifuged at 400 x g for 30 min. The top layers 
were aspirated and the dense mononuclear cell layer was removed and added to HBSS. The 
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mixture was centrifuged at 450 x g for 15 minutes, the supernatant was decanted and the 
pellet was resuspended in 10 ml HBSS and incubated with 10 mllysing solution (0.013 M 
Na2HP04, pH 7.2) for 40 sec. Twenty ml restoring solution (0.1 M PBS, pH 7.4) was added 
and the cells were centrifuged for 15 min at 450 x g. Cells were washed and centrifuged 
twice with HBSS at 450 x g for 15 min and resuspended at 2.5 x 106 cells/ml in RPMI 
(Gibco, GaIthersburg, MD) containing 10% fetal bovine serum, 25 mM HEPES (Gibco) and 
50 ~g/ml gentamicin (Gibco). Cells were plated in triplicate in microtiter plates. 
Concanavalin A (5-10 Ilglml; Gibco) or S. heidelberg LPS (2.5-100 Ilg/ml) were added and 
the plates were incubated at 37°C with 5% CO2 for 48 h for B cell proliferation assays. Cells 
were pulsed with 0.5 IlCi/30 ~13H-thymidine/well, incubated for 18 h and harvested. Values 
are reported as the mean ± SEM stimulation index (defined as experimental values divided by 
negative control values) for pigs in each group. Negative control wells contained cells plus 
RPMI media only. 
RESULTS 
Pigs All pigs were Salmonella-free prior to challenge. No Salmonella was recovered from 
any sample taken from pigs in Group 4 during the study. 
Clinical response No significant increase in temperature was observed for any group. 
Temperatures ranged from 38.1 °C (100.6°F) to 40.9°C (l 05.6°F), with the highest 
temperatures recorded on day 2 (D2). All pigs in Groups 1, 2 and 3 exhibited mild to 
moderate coughing beginning on D2. Within each group several pigs appeared slightly 
depressed and exhibited mild dyspnea or diarrhea. Clinical signs resolved by D13. Group 4 
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exhibited no clinical signs. 
Mortality One pig from Group 1 was euthanized on DI2 after becoming moribund; the final 
temperature was recorded at 40.3°C (104.6°F). At necropsy, Salmonella was recovered from 
BLN, liver, spleen, ICLN, ICl and Mid II. Quantitative levels of Salmonella 
(logIOCFU/gram) in tissues were as follows: tonsil, 0.00; lung, 0.41; ICLN, 2.79; ICl, 4.21; 
Cec Cont, 3.82. 
One pig from Group 3 was euthanized on D8 after becoming moribund. Salmonella 
was recovered from 11114 tissues at necropsy. Quantitative levels of Salmonella in tissues 
were as follows: tonsil, 4.84; lung, 0.00; ICLN, 4.30; ICl, 4.02; Cec Cont, 3.20. Values from 
TNR samples, tissues, antibody responses and lymphocyte stimulation indeces for either of 
these pigs are not included in results. It should be noted that these pigs were poor doers prior 
to initiation of the study and were placed randomly in respective groups. 
Gross patlzology Hemorrhagic and enlarged lymph nodes, consolidation and hemorrhage in 
lungs, and irritation of the epithelium on the ileocolic junction were observed in tissues from 
several pigs in Groups 1,2 and 3. Gross differences in pathology between groups were not 
observed. 
Antemortem bacteriologic results Frequency of positive swabs and loops is shown in Table 
1. All pigs in Groups 1, 2 and 3 had at least one positive swab or loop by D 1. Pigs in Group 
1 had less than 20% TNR samples positive throughout the study. By D5, 93.9% (31/33) of 
TNR samples were positive from Group 3, compared to 61.1% (22/36) samples in Group 2 
and 15.2% (5/33) in Group 1. All groups had at least 1 positive swab or loop throughout the 
study with the exception of Group 1 pigs on D43 when no positive swabs or loops were 
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observed. Percent positive TNR samples are shown in Figure 1. 
The magnitude of fecal shedding is shown in Figure 2. For Groups 1 and 3 shedding 
peaked on D7 (2.95 and 6.17 logs, respectively), whereas Group 2 shedding peaked on D 1 0 
( 4.31 logs). Levels for Group 2 pigs increased slightly on D29 to 2.69 logs and subsequently 
decreased along with the other two groups. All groups shed greater than 1 log throughout the 
study until D36. Group 1 pigs ceased shedding by D36, while Groups 2 and 3 continued 
shedding (.723 and .401 logs, respectively) to D43 when the experiment terminated. 
Postmortem bacteriologic examination Table 2 shows the distribution and frequency of 
positive tissues from each group at each necropsy. Salmonella was recovered from more 
tissues in Group 3 than any other group at 4 and 6 week necropsies. No positive tissues were 
recovered from pigs in Group 1 at 6 weeks PC. Salmonella persisted in Cec Cont, IC}, mid-
ileum, tonsil and MLN of pigs in Groups 2 and 3 through 6 weeks PC. The majority of 
Salmonella positive tissues were gut-associated (ICLN, colon, IC), CLN, Cec Cont, cecum, 
and mid-ileum) and not respiratory-associated (tonsil, MLN, BLN, and lung). From Group 3 
pigs, however, Salmonella was recovered from more respiratory-associated tissues at 2 and 6 
week necropsies. 
Populations of Salmonella recovered from tonsil, IC}, Cec Cont and ICLN are shown 
in Table 3. Although quantitative bacteriologic culture was conducted for lungs, levels were 
below detection limits. Salmonella levels were below detectable limits in Group 1 tissues at 
6 weeks PC and <1 log)o CFU/gram Salmonella were recovered from Cec Cont at 2 and 4 
weeks PC. Levels of Salmonella were greatest in the ICLN at 2 weeks PC from pigs in 
Group 1. Less than 2 logs were recovered from I CLN and Cec Cont from pigs in Group 3. 
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Levels in the IC] and tonsil from Group 3 pigs were greater than 3 logs throughout the study. 
Numbers of Salmonella recovered from tonsils from all groups were highest at 4 weeks PC. 
Serum antibody responses Figures 3a and 3b show optical density values for IgM or IgG 
response for each group at each necropsy. Peak IgM ODs occurred at 2 weeks PC for Groups 
2 and 3 and at 4 weeks PC for Group 1. Average OD values were undetectable for Group 2 
and 3 at both 4 and 6 weeks PC. Peak IgG optical densities occurred at 6 weeks PC for 
Groups 2 and 3. Group 1 had a measurable response at 4 weeks PC but no detectable 
response at 2 or 6 weeks PC. 
Blastogenesis assays Lymphocyte blastogenic responses to S. heidelberg LPS are shown in 
Figure 4. Differences between groups were not observed until D27 PC, when the average 
stimulation index for Group 3 was greater than the other three groups. Subsequently, a 
decreased response for Group 3 was noted on D43, when compared to all other groups. No 
differences in stimulation indices for all groups were observed with Concanavalin A. 
DISCUSSION 
Regardless of dose, clinical signs of infection were either inapparent or mild in all 
challenge inoculated groups. It was not surprising that clinical signs were inapparent in pigs 
challenged with 103 CFU, however, even at high doses, pigs did not appear to be clinically 
ill. Mild coughing seemed to be the predominant indicator of infection, with a few pigs 
having sporadic diarrhea. This clinical presentation is atypical when compared to infection 
with S. fyphimurium (8, 10) or S. choleraesuis (12, 25), which usually result in more 
noticeable clinical signs of infection such as diarrhea, fever, dyspnea, anorexia and lethargy. 
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Two explanations for the difference in clinical presentation may be attributed to route 
of inoculation and serotype. An intranasal inoculation has been shown to produce more 
severe clinical disease following challenge with S. choleraesuis (12). We assumed the same 
effect would be seen using S. heidelberg. In a study done by Reed et al. (22), oral challenge 
appeared to produce more severe disease when S. heidelberg was used. However, the 
challenge dose was higher (1010 CFU). This suggests that had S. heidelberg been 
administered via the oral route, different clinical disease patterns may have developed. 
The only significant clinical sign we observed was coughing, possibly due to a 
respiratory infection brought about by intranasal inoculation. Reed et al. (22) initially 
reported a difference in clinical presentation and pathological changes induced by S. 
heidelberg when compared to S. choleraesuis or S. typhimurium. However, the lack of 
clinical signs occurred after pigs had been reinfected with 1010 CFU (22). Pigs in this study 
received only a primary challenge. Additionally, Reed et al. (22) observed fluid diarrhea 48 
hours PC for three days, whereas few pigs in this study had noticable diarrhea. Our results 
suggest that carriage of S. heidelberg in swine can be clinically inapparent which may be 
problematic when a carcass is presented at slaughter. 
Mortality in a Group 3 pig was not unexpected because it has been shown that high 
numbers (> 1 09) of Salmonella in experimentally infected swine can cause mortality (15, 29). 
It seems unusual that the pig in Group 1 died unless other etiologies were present to cofound 
a relatively low level Salmonella infection. As mentioned, both pigs were not thriving as 
well as other pigs at the start of the experiment. We suspect that regardless of placement in 
any group, these pigs would not have done well following challenge. If other etiologies were 
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not involved in mortality associated with the Group 1 pig, death would be attributed to 
infection with Salmonella alone, suggesting that low levels of S. heidelberg can be virulent 
for less than healthy animals. 
A dose dependent relationship was observed for recovery of Salmonella from TNR 
samples and with fecal shedding. However, shedding patterns differed between groups. The 
magnitude of fecal shedding was greatest in pigs in Group 3 and lowest in Group 1 pigs. 
Group 1 pigs were eventually able to clear the infection after D36. However, Groups 2 and 3 
were still shedding low levels up to D43 when the study terminated. A dose of 106 CFU S. 
heidelberg appears to be the minimum dose required to establish an infection lasting at least 
6 weeks. 
Levels of Salmonella recovered from tissues also appeared to be dose dependent. At 
6 weeks PC, high levels were recovered in IC] from pigs in Groups 2 and 3. The ileocolic 
junction was the tissue of predilection. Recovery of Salmonella up to 6 weeks PC from the 
IC] may be indicative of a progression toward the carrier state as described by Gray et al. 
(12). 
Although a dose dependent relationship is observed, these results contrast other 
studies (13) in that S. heidelberg was recovered from pigs challenged with 103 CFU for at 
least 36 days PC. This suggests that pigs exposed to low doses of S. heidelberg have the 
ability to become infected with and shed the bacterium in the environment, possibly 
contaminating other naive pigs for a longer period of time. Gray et al. (13) demonstrated that 
naive pigs can become infected with and shed S. choleraesuis following exposure to 
environmental levels of ~ 2.6 logs. In a herd, S. heidelberg may be difficult to monitor 
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because of lack of clinical disease and may be more difficult to eradicate because exposure to 
very low doses may result in some degree of persistence. 
For Group 3, Salmonella continued to colonize the tonsil and IC] throughout the 
experiment. Because of this persistent infection, immune function may be compromised at a 
challenge dose 2:109 CFU. These results coincide with blastogenic responses to S. heidelberg 
LPS. At 6 weeks PC, some level of immunosuppression is observed in Group 3 pigs. 
Immunosuppression has also been suggested following challenge with S. choleraesuis (13). 
The IgG and IgM responses were classic for all groups and confirm exposure to the 
antigen. A mix-ELISA to monitor a herd immune response has been proposed (19). Use of 
the heat extract antigen as described here may produce comparable results and warrants 
further investigation. 
In conclusion, pigs infected with low to high doses of Salmonella heidelberg may not 
show obvious signs of disease but may become persistently infected. This makes detection 
of inf~cted swine difficult and may result in presentation of swine at slaughter with an 
inapparent Salmonella infection. 
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FIGURE LEGENDS 
Figure 1 - Qualitative recovery of Salmonella heidelberg from TNR samples. L Group 1: 
103 CFU, __ Group 2: 106 CFU, --- Group 3: 109 CFU) 
Figure 2 - Quantitative recovery of Salmonella heidelberg from fecal pools. See Figure 1 for 
legends. Reported values are CFU/gram as calculated by the most probable number method 
for each group. 
Figure 3 - a- Serum IgM responses of swine following intranasal challenge with 103 (Group 
1), 106 (Group 2), or 109 (Group 3) CFU S. heidelberg. Salmonella heidelberg heat extract 
was used as the antigen. 
b- Serum IgG responses of swine following intranasal challenge with 103 (Group 1), 106 
(Group 2), or 109 (Group 3) CFU S. heidelberg. Salmonella heidelberg heat extract was used 
as the antigen. 
Figure 4 - In vitro blastogenic responses to S. heidelberg LPS from swine challenged with 
103 (Group 1), 106 (Group 2), or 109 (Group 3) CFU S. heidelberg. Group 4 represents 
uninoculated controls. 
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Table 2 - Qualitative recovery of Salmonella heidelberg from the tissues of experimentally 
infected swine 
Groups 
2 3 
2wka 4wk 6wk 2wk 4wk 6 wk 2wk 4wk 6wk 
Tonsil 0/4b 0/4 0/3 114 114 114 2/4 4/4 2/3 
MLN 0/4 0/4 0/3 3/4 3/4 114 4/4 3/4 2/3 
BLN 1/4 0/4 0/3 1/4 1/4 1/4 2/4 0/4 0/3 
Lung 0/4 0/4 0/3 0/4 0/4 0/4 114 114 0/3 
Liver 0/4 0/4 0/3 0/4 0/4 0/4 0/4 114 0/3 
Spleen 0/4 0/4 0/3 114 1/4 114 0/4 0/4 0/3 
ICLN 3/4 4/4 0/3 4/4 3/4 114 1/4 3/4 0/3 
Colon 0/4 2/4 0/3 0/4 114 0/4 0/4 2/4 113 
CLN 2/4 114 0/3 2/4 0/4 114 2/4 114 0/3 
Cec Cont 0/4 1/4 0/3 1/4 1/4 1/4 2/4 2/4 1/3 
Cecum 2/4 0/4 0/3 3/4 114 0/4 114 3/4 113 
IC] 2/4 2/4 0/3 3/4 3/4 2/4 2/4 3/4 2/3 
MidIl 114 114 0/3 1/4 1/4 3/4 0/4 2/4 1/3 
SW 0/4 0/4 0/3 0/4 114 0/4 2/4 2/4 0/3 
Total pos 11/56 11156 0/42 20/56 17/56 12/56 19/56 27/56 10/42 
% positive 19.6 19.6 0 35.7 30.4 21.4 33.9 48.2 23.8 
a- weeks post-challenge 
b- number positive/number sampled 
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Table 3 - Mean populations of Salmonella heidelberg recovered from tissues 
Necropsy 
---L ~ ...n.... 
Group 1 tonsil o.ooa 2.73 0.00 
ICLN 2.95 1.89 0.00 
IC] 1.93 4.06 0.00 
Cec Cont 0.78 0.67 0.00 
n 11 7 3 
Group 2 tonsil 1.25 3.57 0.47 
ICLN 2.81 2.35 NQ_Pb 
IC] 3.24 2.77 5.50 
Cec Cont 4.77 0.17 0.25 
n 12 8 4 
Group 3 tonsil 3.42 5.03 4.24 
ICLN 1.90 0.04 0.00 
IC] 4.29 4.71 3.85 
Cec Cont 1.89 1.92 0.52 
n 11 7 3 
a- values reported are loglOCFU/gram 
b- NQ-P - not quantifiable but positive by qualitative bacteriologic examination 
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CHAPTER 3. EFFECT OF NAXCEL® AND BAYTRIL® ON 
SALMONELLA HEIDELBERG INFECTION IN SWINE 
A paper submitted to Antimicrobial Agents and Chemotherapy 
Heidi L. Holcomb\ Paula J. Fedorka-CrayB* and Linda K. Tollefsonc 
ABSTRACT 
The effect of 2 antimicrobics on Salmonella heidelberg infection in swine was 
studied. Forty-four Salmonella-free pigs were placed into 4 groups. Groups 1,2 and 3 (n=12 
each) received 109 CFU S. heidelberg intranasally (IN) at 7 weeks of age. Group 4 (n=8) 
served as controls. On day 2 (D2) through D4 post-challenge (PC), Group 1 received 4 
mg/kg Naxcel® (ceftiofur) intramuscularly (1M) and Group 2 received 4 mg/kg Baytril® 
(emofloxacin) 1M. Groups 3 and 4 did not receive antibiotics. Pigs (4/group and 1 control) 
ADept. MIPM, Ibwa State University, Ames, IA 50011 
BEnteric Diseases and Food Safety Research Unit, USDA-ARS-National Animal Disease 
Center, 2300 Dayton Rd., Ames, IA 50010 
cDivision of Voluntary Compliance and Hearings Development, FDA-CVM, HFV-240, 7500 
Standish PI., Rockville, MD, 20855 
Running Title: Effect of antibiotics on S. heidelberg infection in swine 
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were necropsied at 2,4 and 6 weeks post-challenge (PC). Tonsil and nasal swabs, rectal 
loops, rectal temperatures, blood and clinical signs were monitored throughout the study. 
Mild to moderate diarrhea and coughing were observed in Groups 1,2 and 3, through D13. 
Groups 1 and 2 had 58.3% and 5.6% total positive swabs and loops on D5 PC, respectively, 
while Group 3 had 88.9% total positive swabs and loops. Additionally, on D5 Groups 1 and 
3 were shedding 4.05 and 5.3710g)o CFU/g feces, respectively, while Group 2 was not 
shedding detectable numbers of Salmonella. However, by DlO, shedding increased to 3.42 
and 1.94 10glO CFU/g feces for Groups 1 and 2, respectively, while Group 3 levels decreased. 
More tissues were positive from Group 3 than any other group at each necropsy. The tissues 
colonized with the highest numbers of Salmonella were the tonsil from Group 1 and ileocolic 
junction from Groups 2 and 3. No increase in resistance was observed for any isolate 
obtained throughout the study. Baytril® appeared to be more effective than Naxcel® in 
reducing Salmonella numbers. However, these data indicated that regardless of the antibiotic 
. 
used, an initial decrease in numbers of Salmonella shed into the environment is followed by 
an increase after cessation of treatment. 
keywords: antibiotic, Salmonella, resistance 
INTRODUCTION 
Salmonella is a food-borne pathogen commonly associated with infections in swine 
(25). Following infection, many Salmonella serotypes are known to persist in swine, 
including S. typhimurium (8), S. choleraesuis (14), and S. heidelberg (15). Contamination of 
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food products, including pork and pork products, may be the result of persistently infected 
carrier pigs which harbor the bacteria with no outward signs of clinical disease (22, 31). 
Salmonella heidelberg ranks as the fourth most frequently isolated Salmonella 
serotype from swine (10) and humans (2). As with other non-host adapted serotypes, with 
the exception of S. typhimurium, S. heidelberg has received little attention. Reed et al. (24) 
suggested a different clinical and pathological presentation occurs following infection with S. 
heidelberg when compared to infection with other serotypes. We have determined that S. 
heidelberg persists in swine without causing noticible clinical signs of disease regardless of 
infectious dose (15). 
Antibiotics have been used to control the spread and reduce shedding of salmonellae 
in swine (29). Medicated feed has been shown to be efficacious in the reduction of bacterial 
infections (11, 16, 17,30). Use ofCephamycin C reduced the febrile response and shedding 
levels of S. choleraesuis in swine following challenge (16) . 
. Naxcel® (ceftiofur sodium) is a p-Iactam antibiotic in the class of third generation 
cephalosporins. It has a broad spectrum of activity, particularly against Gram-negative 
bacteria and its mode of action is based on inhibition of cell wall synthesis (1). Naxcel® is 
primarily used to treat respiratory infections in swine caused by Actinobacillus spp., S. 
choleraesuis and Pasteurella spp. 
Baytril® (enrofloxacin) is a fluoroquinolone antibiotic with a broad spectrum of 
activity against Salmonella, Mycoplasma, Brucella, E.coli, Klebsiella, Proteus, Pseudomonas 
aeruginosa and Staphylococci (3). It acts as a DNA gyrase inhibitor and is particularly 
effective against intracellular pathogens (32). In Europe, it is marketed under the trade name 
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Baytril® and is approved to treat salmonellosis in food producing animals. 
The objective of this study was to determine the effect of two antimicrobics (ceftiofur 
and enrofloxacin) on Salmonella heidelberg infection in swine. 
MATERIALS AND METHODS 
Swine. Source sows were cultured for Salmonella pre- and post-farrowing. At 
approximately 14 days of age, 44 pigs were weaned from culture-negative sows and 
transported to isolation facilities at the National Animal Disease Center in Ames, Iowa. Pigs 
were raised in isolation as previously described (9). Rectal loops and fecal pools were 
collected from pigs weekly for 4 weeks prior to challenge. 
Bacterial strain and culture methods. A clinical isolate of S. heidelberg, 2SKS-7, was 
obtained from the National Veterinary Services Laboratories and used as the challenge strain 
(IS). The resistance pattern of the isolate was determined by using a custom made panel for 
the Sensititre system (Table 1; Accumed, Westlake, OH). 
The challenge culture was made by inoculating S ml of Luria Bertani (LB) broth with 
-1 00 ~l of frozen stock and incubating the broth stationary and overnight, at 37°e. A 1 % 
inoculum was transferred to 2S0 ml of fresh LB and incubated at 37°C and ISO rpm for 
approximately 3.S hours. The culture was centrifuged at 10,000 x g for 20 minutes and the 
pellet was resuspended in 30 ml ofO.lM phosphate buffered saline (PBS, pH 7.2). The 
culture was adjusted to a final concentration of 1.43 x 109 CFU/ml (OD6oo=1.0S3). Final 
concentration was confirmed by plate counts on trypticase soy agar. 
Experimental Procedure. Forty-four pigs were randomly assigned to 4 groups (Groups 1,2 
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and 3, n=12/group; Group 4, n=8) at 7 weeks of age (day 0) and weighed. Pigs were 
challenged intranasally (IN) with 1 ml (0.5 ml in each nostril dropwise, alternating nostrils) 
of 109 CFU/ml Salmonella heidelberg. Pigs in Group 1 were treated intramuscularly (IM) 
one time daily for 3 days beginning on D2 PC with 4 mglkg Naxcel®, while pigs in Group 2 
were treated 1M for 3 days beginning on D2 PC with 4 mglkg Baytril®. Group 3 pigs served 
as challenge controls and Group 4 pigs (n=8) served as uninoculated negative controls. 
After challenge, pigs were observed for clinical signs of infection. Tonsil and nasal 
swabs, rectal loops (Midwest Veterinary Supply, Des Moines, IA; TNR) and rectal 
temperatures were obtained daily for the first week and then weekly thereafter. Fecal pools 
were collected for quantitative bacteriologic culture on days 2,5, 7, 10, 13,20,29,36 and 43 
PC. Pools were obtained by gathering fresh feces in each pen, homogenizing the entire 
amount and randomly selecting approximately 10 grams. Blood was collected for serum on 
days 11,27 and 41 PC. 
. 
Necropsies were conducted on 4 pigs from each challenge group and one pig from the 
control group at 2, 4 and 6 weeks PC. Aseptic technique was used in the collection oftissues 
which included tonsil, mandibular lymph node (MLN), bronchiole lymph node (BLN), lung, 
liver, spleen, colon, colonic lymph node (CLN), ileocolic lymph node (ICLN), ileocolic 
junction (ICl), cecal contents (Cec Cont), cecum, middle ileum (Mid II) and stomach wall 
(SW). 
Bacteriologic culture. Bacteriologic culture was performed as previously described (15). 
Briefly, all TNR samples, fecal pools and tissues were cultured in tetrathionate broth (Difco 
Laboratories, Inc., Detroit, MI) for 48 hours at 37°C, then transferred to Rappaport RIO 
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medium (28; Difco). After incubation at 37°C overnight, samples were streaked onto xylose-
lysine-Tergitol 4 (XLT4) agar plates (Difco) and incubated 24 hours at 37°C. All colonies 
typical of Salmonella were inoculated into triple sugar iron agar (Difco) and lysine iron agar 
(Difco) for biochemical confirmation. Presumed positive colonies were serogrouped by 
agglutination using Salmonella 0 antiserum Group B (Difco). Throughout the study at least 
one positive sample per pig was sent to the National Veterinary Services Laboratories for 
serotyping. 
Tonsil, lung, ICl, Cec Cont and ICLN were obtained at each necropsy for most 
probable number analysis (33). Results are recorded as mean values from each group. 
Antigen preparation. Salmonella heidelberg lipopolysaccharide (LPS) antigen was 
prepared as described by Morrison and Leive (21) and lyophilized for use in lymphocyte 
blastogenesis assays. Heat extract antigen was prepared for use in ELISA assays as described 
by Gray et al. (12). Briefly, ~1001ll of frozen (-70°C) stock culture was inoculated into lL 
LB broth and incubated at 37°C and 220 rpm. After 16 hours, the culture was centrifuged at 
15,000 x g for 10 min. The pellet was resuspended in 1110 volume ofO.lM PBS (PH 7.2) 
and heated in a 60°C water bath for 1 hour with periodic agitation. Cells were centrifuged at 
19,000 x g for 6 minutes and the supernatant was filtered through a Millex-GV 0.22 Ilm filter 
(Millex-GV, Millipore, Bedford, MA) and stored at -70°C until use. Protein concentration 
was determined as described by Bradford (5) using bovine serum albumin as the standard. 
Lympbocyte proliferation assay. Serum from pigs was obtained on days 11, 27 and 41 PC 
for blastogenesis assays and performed as previously described (15). Microtiter plates 
(Dynatech) containing concanavalin A (5-10 Ilg/ml; Gibco, Gaithersburg, MD) or S. 
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heidelberg LPS (2.5-100 Ilg/ml) were inoculated with cells in triplicate and incubated with 
5% CO2 at 37°C for 48 hrs and then pulsed with 0.5 IlCiI30 III 3H-thymidine/well. Cells were 
harvested after 18 hrs. Values are reported as mean± SEM stimulation index (experimental 
values divided by control values) for pigs in each group. Wells containing RPMI media plus 
cells served as negative controls. 
Enzyme linked immunosorbent assay. ELISA assays were performed as described by 
Gray et al. (12). Antigen concentration was adjusted to 4 Ilg S. heidelberg protein/well. 
Conjugate, goat anti-swine peroxidase IgM (Kirkegaard & Perry Laboratories, Inc., 
Gaithersburg, MD) or IgG (Kirkegaard & Perry), was diluted 1 :2000. The substrate was 
3,3'5,5 tetramethylbenzidine microwell substrate (Kirkegaard & Perry) and the reaction was 
stopped by the addition of 1 % sulfuric acid after 10 minutes. Plates were read using a 
Dynatech MR7000plate reader (Dynatech Laboratories, Inc., Chantilly, VA) at a reference 
wavelength of 41 0 nm and a test wavelength of 450 nm. Optical densities were determined 
by subtracting the mean control value from the mean experimental value for each group. 
RESULTS 
Swine. All pigs were culture negative for Salmonella prior to challenge. Group 4 pigs 
remained culture negative throughout the study. 
Clinical signs. Temperatures remained normal throughout the study with the exception of 
D2 in which 1 pig from Group 1 had a temperature of 41.4°C (1 06.5°P) and 1 pig from Group 
3 had a temperature of 41.8°C (107 .3°F). Mild to moderate diarrhea was observed in several 
pigs in each challenge group through D7 PC. Slight coughing was detected in all groups 
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through D 13 PC. Dyspnea was infrequently observed in several pigs in Groups 1 and 2 
through D9 PC. No clinical signs were observed in Group 4 pigs. 
Pathology at necropsy. Hemorrhagic and consolidated lungs, enlarged and hemorrhagic 
lymph nodes, reddened intestinal epithelia, fibrinous adhesions on lungs or peritoneal cavity 
and hemorrhages in liver and spleen were observed in several pigs from all groups. Pigs in 
Group 4 ditl not have visible pathological manifestations. 
Antemortem bacteriologic results. Figure 1 and Table 2 show distribution of positive TNR 
samples for each group. On D5 PC, Group 3 pigs had 88.9% positive samples, while pigs in 
Groups 1 and 2 had 58.3% and 5.6% positive samples, respectively. Percent positive 
samples from both treated groups increased after D5 PC and peaked on D7 PC for Group I 
and D13 PC for Group 2. After a decline in numbers of positive samples on D29 PC, an 
increase was observed on D36 PC to 50% in Groups 1 and 2. At least one positive sample 
was recovered from each group on D43 PC. 
The magnitude of fecal shedding is shown in Figure 2. On D5 PC, Groups 1 and 3 
shed greater than 4 logs while no Salmonella was detected from Group 2 fecal pools. An 
increase in fecal shedding was observed after D5 PC for Group 2 pigs while Group 1 pigs 
began shedding more Salmonella after D7 PC. By D36 PC, levels were low (0.06 logs) in 
Group 2 pigs, while Groups 1 and 3 were shedding 0.80 and 0.97 logIO CFU/g feces, 
respectively, through D43. No salmonellae were recovered from feces of pigs in Group 2 on 
D43 Pc. 
Postmortem bacteriologic results. Frequency of recovery of positive tissues at each 
necropsy is shown in Table 3. At 6 weeks PC, Groups 1 and 3 had more tissues that were 
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positive (35.7% and 42.9%, respectively) than Group 2 (12.5%). Group 1 showed a slight 
increase in numbers of positive tissues at 6 weeks (35.7%), while numbers of positive tissues 
for weeks 4 and 6 were the same for Group 3 (42.9%). Group 3 had the highest percentages 
of respiratory-associated (54.2%; tonsil, MLN, BLN, lung) and gut-associated tissues 
(65.5%; CLN, colon, ICLN, IC], Cec Cont, cecum, Mid II) that were positive. All three 
groups had more numbers of positive tissues from gut-associated tissues than respiratory-
associated tissues. 
Quantitative analyses of tonsil, lung, ICLN, IC] and Cec Cont are shown in Table 4. 
Greater than 2.5 logto CFU/g of tissue were recovered from the tonsil and IC] from all 
groups throughout the study. The IC] was the tissue of predilection in Groups 2 and 3, while 
Group 1 had the highest numbers of Salmonella in tonsil. No salmonellae were recovered 
from the ICLN of any group at 6 weeks PC, while Salmonella numbers remained greater than 
3 logto CFU/g of tissue in the IC] at each necropsy. Numbers of Salmonella in cecal contents 
increased at 6 weeks PC for Groups 1 and 2 (1.2710g1o CFU/g of tissue and 4.01 loglo CFU/g 
of tissue, respectively), while levels decreased in Group 3 pigs (1.22 Iog1o CFU/g of tissue). 
Numbers of Salmonella in the lungs increased at 4 weeks in Groups 1 and 3 but declined at 6 
weeks PC. 
Serum antibody results. IgM responses for Group 1, 2 and 3 to S. heidelberg heat extract 
antigen are shown in Figure 3a. Optical densities were greatest at 2 weeks PC and decreased 
at 4 and 6 weeks PC for all groups. IgG responses were similar for all groups at 2 and 4 
weeks PC (Figure 3b). However, at 6 weeks PC, Groups 1 and 2 had lower average optical 
densities than Group 3. 
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Lymphocyte blastogenic responses. An decreased response was observed in Group 2 pigs 
at 6 weeks PC when compared to Group 4 pigs (Figure 4). Stimulation increased for Group 1 
pigs throughout the experiment. 
DISCUSSION 
Following treatment with either antimicrobic, an initial reduction in numbers of S. 
heidelberg shed into the environment was observed by D5 PC for Groups 1 and 2. Treatment 
protocol was indicative of regular veterinary applications with ceftiofur, and a 3 day duration 
for enrofloxacin was considered to be appropriate. For pigs, calves and poultry, the typical 
range for treatment length for enrofloxacin is 3 to 5 days (3, 4). Reductions in numbers of 
Salmonella following use of antimicrobics have been reported after treatment with 112.5 mg 
Cephamycin C (16) or after using neomycin and oxytetracycline in feed (30). Merkt et al. 
(20) did not detect Salmonella after a treatment length of 10 days with Baytril in feed at a 
concentration of 200 ppm. In contrast to our study, for all of these studies, treatment length 
was typically longer than 3 days in order to maximize antimicrobic effect. 
Although we observed an initial decrease in numbers of Salmonella recovered, 
following cessation of treatment numbers rapidly increased indicating that elimination from 
the host had not occurred. Persistance of Salmonella in the host has also been reported 
following use of other antimicrobics. After 26 days, lacks et al. (16) isolated S. choleraesuis 
from the ICLN after treating experimentally infected swine with Cephamycin C (337.5 mg) 
for 10 days. Additionally, use of medicated feed has not been totally effective in eliminating 
Salmonella. After more than 28 days of treatment, S. typhimurium was still recovered from 
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tissues (17, 30) and feces (7, 17) following treatment with efrotomycin or oxytetracycline. 
In this study, persistence may be attributed to either challenge with a high infectious 
dose or a relatively short treatment length. Use of enrofloxacin for more than 3 days may be 
indicated to significantly lower numbers of Salmonella and prevent reinfection. 
Additionally, a lower infectious dose may have been more likely to be cleared. Comparable 
results are noted in other studies using a 109 CFU or greater dose of Salmonella (7, 16, 17, 
30). However, Gray et al. (13) demonstrated that the clinical response and persistence of 
Salmonella in pigs naturally exposed to infected pigs shedding less than 3 logs per gram of 
feces parallels a high challenge dose. It is likely, then, that regardless of dose, Salmonella 
will persist following treatment with antimicrobics. 
Although numbers of Salmonella increased after D5 PC, Baytril® appeared to have a 
greater effect on reducing numbers of bacteria than Naxcel®. At D5 PC, numbers of 
Salmonella were reduced 6 logs in Group 2 compared to a 1.3 log reduction in Group 1 pigs. 
This dramatic decrease of 6 logs may be attributed to the ability of enrofloxacin to act on 
salmonellae which had been phagocytosed. In contrast to Naxcel®, Baytril® has been shown 
to be very effective against a variety of intracellular pathogens at relatively low 
concentrations (3). 
Despite intracellular efficacy, persistence of Salmonella was observed in tissues of 
Group 2 pigs. Interestingly, Group 1 and 3 pigs had low numbers of Salmonella in the Cec 
Cont while Group 2 numbers increased by 2.8 logs at 6 weeks PC. No salmonellae were 
detected in fecal pools from Group 2 at 6 weeks while average numbers of Salmonella in Cec 
Cont were high (4.01 loglo CFU/g feces) and at least one pig had 1 positive rectal loop at 6 
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weeks. This suggests that numbers of Salmonella being shed may approach zero while tissue 
levels increase, creating a problem for presentation of animals at slaughter. Use ofNaxcel 
was less effective in reducing numbers of Salmonella and persistence was observed through 6 
weeks. The tissue most often cultured at the slaughter plant for Salmonella is the ICLN. 
Numbers of Salmonella in the ICLN from all three groups were not detected at 6 weeks PC 
based on quantitative analysis, while numbers in the Cec Cont remained high. Culture of the 
ICLN only at slaughter may lead to false negative results which suggests that both the ICLN 
and Cec Cont should be cultured. 
Serum antibody responses observed in this study are comparable to those reported by 
others (12). Blastogenic responses may indicate some level of immunosuppression in Group 
2 by 6 weeks PC which has been previously described (12). Antimicrobics have been shown 
to have both immunoenhancing and immunodepressing properties (27). The immune 
suppression observed in this study does not appear as marked for the challenge control group 
suggesting that the observed effect was due to the antimicrobic and not the infectious dose. 
Immunosuppression following treatment with ciprofloxacin (a fluoroquinolone) has been 
reported (23). 
The opposite effect appears to be occurring with Naxcel in that an immunostimulation 
is observed at 6 weeks PC for Group 1. Since immunostimulation has been reported 
following treatment with cephalosporins, cefotaxime (19) or cefodizime (18, 19,26) and an 
immunosuppression has been observed following exposure to S. choleraesuis (12), the effect 
observed for Group 1may be attributed to use of the antimicrobic and not the infection. 
These data indicate that while antimicrobics may initially decrease the amount of 
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Salmonella shed into the environment, the numbers of Salmonella shed will increase when 
treatment stops. Both antibiotics failed to clear a 109 CFU S. heidelberg infection although 
Baytril® appeared to be more effective than Naxcel® at reducing overall numbers. Further in 
vivo studies using antimicrobics and different Salmonella serotypes are warranted. 
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FIGURE LEGENDS 
Figure 1 - Qualitative recovery of Salmonella heidelberg from combined tonsil, nasal, and 
rectal samples. L Group 1: Naxcel® treated, __ Group 2: Baytril® treated, --- Group 3: 
untreated) 
Figure 2 - Quantitative recovery of Salmonella heidelberg from fecal pools. See Figure 1 for 
legends. Reported values are CFU/gram as calculated by the most probable number method 
for each group. 
Figure 3 - a - Serum IgM responses of swine following treatment with Naxcel® (Group 1), 
Baytril® (Group 2) or untreated (Group 3), to S. heidelberg heat extract antigen. Reported 
values are the mean ELISA IgM specific OD. 
b - Serum IgG responses of swine following treatment with Naxcel® (Group 1), Baytril® 
(Group 2) or untreated (Group 3), to S. heidelberg heat extract antigen. Reported values are 
the mean ELISA IgG specific OD. 
. 
Figure 4 - Two-day in vitro blastogenic responses to S. heidelberg LPS of peripheral blood 
lymphocytes from swine treated with Naxcel® (Group 1) or Baytril® (Group 2) or untreated 
(Group 3). Group 4 consisted of negative control pigs. Assays were performed on days 11, 
27 and 41 PC. Error bars represent the standard error of the mean. 
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Table 1 - Resistance pattern of #25K5-7, swine isolate, S. heidelberg 
Antimicrobic 
amikacin 
amoxicillinl clavulanic acid 
ampicillin 
apramycin 
cefotaxime 
ceftiofur 
ceftriaxone 
cephalothin 
chloramphenicol 
ciprofloxacin 
gentamicin 
kanamycin 
naladixic acid 
neomycin 
piperacillin 
streptomycin 
sulfamethoxazole 
tetracycline 
ticarcillin 
ticarcillinlclavulanic acid 
trimethoprimJsulfamethoxazole 
a-susceptible 
b-resistant 
c-values reported in ~g/ml 
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Table 3 - Qualitative results from tissues of pigs challenged with S. heidelberg 
Group 1 Group 2 Group 3 
Tissue 2a 4 6 2 4 6 2 4 6 
tonsil 4/4b 2/4 0/4 3/4 2/4 2/4 2/4 2/4 3/4 
MLN 4/4 4/4 2/4 4/4 2/4 0/4 4/4 2/4 3/4 
BLN 114 0/4 0/4 4/4 114 0/4 3/4 2/4 2/4 
Lung 0/4 0/4 0/4 1/4 114 0/4 2/4 0/4 1/4 
Liver 114 114 0/4 114 2/4 0/4 0/4 0/4 2/4 
Spleen 2/4 0/4 0/4 0/4 1/4 0/4 114 114 0/4 
CLN 4/4 114 0/4 3/4 114 0/4 4/4 114 114 
Colon 3/4 0/4 1/4 2/4 114 0/4 4/4 3/4 1/4 
ICLN 4/4 2/4 4/4 3/4 3/4 0/4 4/4 2/4 1/4 
ICJ 4/4 1/4 3/4 4/4 3/4 2/4 4/4 2/4 2/4 
CecCont 4/4 2/4 3/4 3/4 114 114 3/4 3/4 2/4 
Cecum 2/4 114 2/4 4/4 114 1/4 4/4 3/4 2/4 
Mid 11 3/4 3/4 4/4 3/4 3/4 0/4 4/4 2/4 3/4 
SW 114 1/4 1/4 4/4 114 1/4 4/4 1/4 114 
tot pos 37/56 18/56 20/56 39/56 23/56 7/56 43/56 24/56 24/56 
%pos 66.1 32.1 35.7 69.6 41.1 12.5 76.8 42.9 42.9 
a-weeks post-challenge 
b-number positive/number sampled 
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Table 4 - Mean populations of S. heidelberg recovered from tissues 
Necro~sx 
2wk 4wk 
Grou~ 1 
tonsil 3.5P 5.57 
lung <0 1.24 
ICLN 2.53 1.25 
IC] 4.98 4.30 
Cec Cont 1.85 0.31 
Grou~ 2 
tonsil 5.03 5.20 
lung NQ-P 0.44 
ICLN 2.85 4.43 
IC] 5.67 5.61 
Cec Cont 2.35 1.20 
Grou~ 3 
tonsil 5.41 3.58 
lung NQ-P 1.21 
ICLN 6.24 0.45 
IC] 5.48 4.53 
Cec Cont 1.77 2.13 
a-data are expressed as loglOCFU/gram tissue 
b-not quantifiable but positive by bacteriology 
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SUMMARY 
These experiments were designed to study the pathogenesis of Salmonella heidelberg 
infections in swine. Since few studies have been published regarding S. heidelberg in swine, 
we attempted to determine the effect of different doses on shedding and persistence in swine. 
Additionally, we attempted to determine the effect of antibiotics on S. heidelberg infection in 
a second study. 
In the first study, three groups of pigs inoculated with different concentrations of S. 
heidelberg were monitored for clinical signs of infection, qualitative analysis of tonsil and 
nasal swabs and rectal samples (TNR) and tissues, and quantitative analysis of shedding and 
tissues. Necropsies were performed three times during the study, ending at six weeks post-
challenge. Our data indicated a dose dependent relationship regarding shedding, numbers of 
positive tissues and TNR samples. Results were atypical when compared to Salmonella 
infections with S. typhimurium or S. choleraesuis. Pigs infected with 103 CFU S. heidelberg 
were still shedding by D36, whereas pigs infected with S. typhimurium or S. choleraesuis 
typically can clear an infection in less time. 
Additionally, S. heidelberg produced inapparent or mild disease regardless of dose. 
Typically at two days post-challenge, clinical signs such as a febrile response, diarrhea, 
dyspnea and lethargy can be observed in pigs infected with S. typhimurium or S. 
choleraesuis. The differences observed in this study are problematic to the industry in that 
salmonellae can persist in a herd, without giving rise to clinical signs of illness, resulting in 
presentation of animals at slaughter that harbor salmonellae. 
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In the second study, pigs were inoculated with 109 CFU Salmonella heidelberg and 
treated for 3 days with ceftiofur sodium or enrofloxacin after clinical signs were first 
observed. Similar parameters were monitored following challenge. We initially observed a 
reduction in numbers of Salmonella, with enrofloxacin most effective until D5. This may be 
attributed to the intracellular efficacy of enrofloxacin when compared to ceftiofur. However, 
when treatment ceased, shedding and numbers of positive TNR samples increased. 
Additionally, tissues continued to be colonized throughout the experiment, regardless of 
treatment. High numbers were present in tissues, primarily the ICJ and tonsil. These 
increases may be due to the inability of the host to clear a high dose or treatment length not 
being long enough to clear the infection. Additionally, it has been reported that many 
antimicrobics have an immunosuppressing or immunoenhancing effect on the host, thus 
affecting the hosts's ability to clear an infection. 
These two studies indicate that S. heidelberg is capable of persisting in a host and 
resisting treatment, even following use of an intracellular antibiotic. 
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APPENDIX 
Bradford Protein Assay 
Method: Bradford, M.M. 1968. A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principles of protein dye-binding. Anal. 
Biochem. 72:248-254. 
I. Solutions 
A. 0.9% Saline (PH 7.0) 
NaCI 9.0 L 
dd H20 1.0 L 
B. Protein Dye Reagent Concentrate (BioRad Cat # 500-0006) 
Store at 4°C. Discard after 1 year. 
C. Bovine Serum Albumin Frac V Standard (l mg/ml) 
BSA (Sigma #A4503) 250 mg 
0.9% Saline 250 ml 
Distribute 1.0 ml aliquots in 1.5 ml microfuge tube. Store at -20°C. 
II. Protocol 
1. Prepare working solution ofBSA by diluting frozen BSA Standard (solution C, 
above) 1:10 with 0.9% saline. 
2. Prepare a BSA standard curve as follows: 
Final BSA conc. ml of 
blg/ml working solution 
25 1.00 
20 .80 
15 .60 
10 .40 
8 .32 
6 .24 
4 .16 
2 .08 
o .00 
NOTE: Only glass test tubes may be used in this procedure. 
mlof 
normal saline 
3.00 
3.20 
3.40 
3.60 
3.68 
3.76 
3.84 
3.92 
4.00 
3. Dilute test samples in normal saline so that the protein concentration will lie within 
the linear range of the standard curve. Dilutions of 1: 1 0, 1: 1 00 and 1: 1 000 are 
usually sufficient. Test samples are usually made so that the final volume is 1.0 ml. 
4. Using a glass pipette, add 1 ml Protein Dye Reagent Concentrate to each dilution of 
the standard curve. Only 0.25 ml of dye concentrate is required for the 1.0 ml test 
samples. Mix. Allow color to develop for 5 min. 
5. Read absorbance at 595 nm within 1 hour. 
6. Plot standard curve and calculate protein concentration. 
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Endotoxin Preparation 
by Thomas J. Stabel 
Method: Morrison, D.C. and L. Leive. 1975. J BioI. Chern. 250:2911-2919. 
1. Pellet 2 L of cells at 7,000 rpm for 15020 min at 4°e. Note: Record empty weight of each 
centrifuge bottle before using. 
2. Resuspend bacteria in cold 0.85% saline at a concentration of 250 gIL (eg. 62.10 g - 56.61 
g (empty bottle weight) = 5.49 g pellet; 250 g/1000 ml = 5.49 g/x ml, x = 21.96 ml saline). 
3. Add equal volume of H20-saturated I-butanol (top layer); stir 15 min. 
4. Centrifuge at 35,000 x g (16,000 rpm) for 20 min. 
5. Separate aqueous phase (lower) from upper phase and save aqueous phase. 
6. Twice re-extract upper phase (I-butanol) and insoluble precepitate (i.e. everything else) 
with half the initial volume of saline. Combine aqueous extracts and centrifuge. 
7. Add non-specific protease (from Streptomyces griseus; Boerhringer Mannheim) in 0.2 M 
Na2HP04 buffer, pH 7.0, to aqueous extract for a final enzyme concentration of20 /lg/ml (eg. 
prepare 2 mg protease in 1 ml buffer; add 0.1 ml of 2 mg/mi solution per 10 ml aqueous 
extract). Incubate overnight at 37°C. 
8. Remove white flocculent precepitate at 10,000 x g for 40 min. Carefully remove thin 
insoluble layer on top of centrifuge tube by aspiration. 
9. Concentrate extract by ultrafiltration with an Amicon pressure cell and a XM -1 OOa filter 
(76 mm #14243; Amicon), pressure = 25-30 psi. 
10. Wash extract in the Amicon cell with saline at a constant volume until effluent shows no 
absorbance at 260 nm. Collect effluent in 50 ml conicals (eg. started with 60 ml extract; conc. 
to 30 ml and then repeatedly added 30 ml volumes). 
11. Dialyze extensively against H20, lyophilize and store at -20 to -70°e. 
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Lymphocyte Blastogenesis Assay 
Reagents: by Thomas J. Stabel 
A. Phospate buffered saline (PBS), pH 7.2 
32 g NaCI 
4.6 g Na2HP04 
0.8 g KH2P04 
0.8 g KCI 
3.5 L dd H20 
Adjust pH to 7.2 and q.s. to 4 L with dd H20. Autoclave and store at 4°C. 
B. Hanks Balanced Salt Solution (HBSS; w/o calcium or magnesium) 
8.0 g NaCI 
0.4 g KCI 
0.06 g Na2HP04 
0.06 g KH2P04 
1.0 g dextrose 
0.35 g NaHC03 
Adjust pH to 7.4, q.s. to 1 L with dd H20 and filter sterilize. 
C. Heparin (10,000 units/m!) dilute in PBS, pH 7.2, and filter sterilize. Store at 4°C. 
D. Ficoll-Paque (Pharmacia, Cat. #17-0840-02) warmed to room temperature 
E. Gentamicin solution (5 mg/ml) 
4 ml gentamicin stock (50 mg/ml; Sigma, Cat. #G-1397) 
36 ml PBS, pH 7.2 (sterile) 
Dispense 1 and 5 ml aliquots and store at -20°e. 
F. Culture media (RPMI 1640 containing 25 mM HEPES, L-Glutamine, supplemented with 
10% FBS and 50 ~g/ml gentamicin) 
50 ml FBS (Hyclone; heat-inactivated 56°C, 30 min) 
5 ml gentamicin solution (Reagent E) 
500 ml RPMI 1640 (Gibco, Cat. #380-2400AJ; already containing 
HEPES and L-Gln) 
G. Lysing solution (0.013 M phosphate buffered H20) 
80 ml 0.15 M Na2HP04 
1500 ml dd H20 
Adjust pH to 7.2 with 0.15 M KH2P04 (-4 mIlL), q.s. to 2000 m! with dd H20. 
Autoclave and store at 4°C. 
H. Restoring solution (PBS, 2.7%) 
80 m! 0.15 M Na2HP04 
1500 ml dd H20 
54 g NaCl 
Adjust pH to 7.4 with 0.15 M KH2P04 (-4 mIlL), q.s. to 2000 mi with dd H20, 
Autoclave and store at 4°C. 
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1. 3H-thymidine solution (33.34 ~Ci/ml) 
48.34 ml culture media (Reagent F) 
1.66 ml 3H-thymidine (1 ~Ci/ml; Amersham Cat#TRA.120) 
Store in a clearly labeled 50 ml Blue Max tube at 4°C. 
Note: Withdraw tritium from sterile duoseal vial with 1 ml tuberculin syringe and 25-g 
needle. All work should be done in laminar flow hood on disposable bench paper clearly 
labeled with radioactve tape. Dispose of solid waste in 3H solid waste can. 
Peripheral Blood Lymphocyte (PBL) Isolation: 
1. At necropsy, collect porcine whole blood in sterile 10 ml Vacutainer tubes with heparin. 
Note: At non-terminal bleeding dates, collect whole blood by jugular venapuncture using a 
15 ml draw heparin Vacutainer tube with 20 gaugell.5" needle (three tubes/animal). 
2. Dilute 30 ml of whole blood (1:1) with 10 ml HBSS (w/o Ca++ or Mg++). Layer 20 ml of 
diluted blood over 9 ml Ficoll-Paque per 50 ml Blue Max tube (two tubes per animal). 
3. Centrifuge at 400 x g (1400 rpm using Sorva1l6000R; 1300 rpm using IEC PR 7000; 1350 
rpm using Beckman TJ-6, 3.8) for 30 min at 18°C with acceleration and brake "off'. 
4. Aspirate off and discard enough of the upper plasma layer to allow transfer of the "Buffy 
Coat" (i.e. PMNs) with a 10 ml pipet to a clean 50 ml Blue Max tube. Fill remainder of tube 
with HBSS (w/o Ca++ or Mg++). 
5. Centrifuge at 450 x g (1474 rpm in Sorvall 6000R; 1400 rpm in IEC PR 7000; 1450 rpm in 
Beckman TJ-6, 4.0) for 10-15 min at 18°C. 
6. Pour off supernatant and resuspend cells in 10 ml HBSS (w/o Ca++ or Mg++). 
7. Add 10 mllysing solution, mix, and let set for 40 sec. 
8. Add 20 ml restoring solution. Centrifuge cells as in Step #6. 
9. Wash cells 2x with HBSS (w/o Ca++ or Mg++). Centrifuge cells as in Step #6. 
10. Resuspend cells in -2 ml media and count using Celltrak-3B Cell Counter. (Optional: Do 
Trypan Blue viability test.) 
Cell Proliferation Assay: 
1. Dilute porcine cells to 2.5 x 106 cells/ml in media and dispense in 96-well microtiter plates 
(1 00 ~l/well; in triplicate) containing 100 ~l/well of appropriately diluted mitogens and/or 
antigens (done in triplicate). 
Examples: ConA (Sigma, Cat #C-5275) 
PHA-P (Sigma, Cat #L-9132) 
PWM (Sigma, Cat #L-9379) 
Salmonella endotoxin 
5.0-10.0 ~g/ml (final cone) 
2.5-5.0 ~g/ml 
1.0-5.0 ~g/ml 
2.5-50.0 ~g/ml 
Note: Remember to prepare mitogens and antigens 2x more concentrated than desired final 
concentration. As a control include media and cells. 
2. Incubate plates in a 37°C, 5% CO2 moisture incubator for 48 hours (Note: For T-cell 
proliferation studies incubate 5 days). 
3. Pulse cells with 0.5 ~Ci/30 ~l 3H-thymidine (Reagent I) per well. Incubate 18 h and 
harvest. 
Antigen Preparation 
Salmonella serotypes 
S. typhimurium 
S. choleraesuis 
S. enteritidis 
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ELISA 
Source 
NADC 
NADCICurtiss 
ATCC 
by Gray and Cray 1995 
S. anatum 
S. heidelberg 
Strain 
798 
3246pp 
21108 
281-43 
25K5-7 
NAHMS COFE '94 
NAHMS Swine '95 
Rotors: SS-34 (small) - #5; GSA (large) - #10 
Materials: 
Luria Bertani broth 
109 tryptone 
5 g yeast 
10 g NaCl 
Add 950 ml dd H20, adjust to pH 7.0, q.s. to 1 L 
Autoclave 
Phophate Buffered Saline (0.1 M PBS) 
2.28 g Na2HP04 (dibasic) 
0.46 g NaH2P04 (monobasic) 
9.00 gNaCl 
1 L ddH20 
Adjust to pH 7.2 
Conjugate 
Goat anti-swine IgG or IgM peroxidase conjugate 
KPL, Gaithersburg, MD 
Wash Buffer 
1 L 0.1 M PBS 
2 ml 5% Tween 20 
Substrate 
TMB micro well peroxidase substrate 
KPL, Gaithersburg, MD 
To make heat extracted antigen from each strain: 
5% Tween 20 
5 ml Tween 20 
95 ml dd H20 
Diluent Buffer 
0.5 g BSA 
Block 
200 III 5% Tween 20 
100 ml 0.1 M PBS 
1 gBSA 
100 ml 0.1 M PBS 
Stop Solution (0.18 M) 
1 ml 18 M sulfuric acid 
99 ml dd H20 
1. Scrape top of -70°C frozen stock culture with a sterile cotton swab. 
2. Place swab in 1 L ofLB broth and incubate at 37°C, 220 rpm for 16 h. 
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3. Centrifuge culture at 15,000 x g (12,000 rpm) for 10 min. at 4°C and resuspend pellet in 
1 % original volume with 0.1 M PBS. 
4. Heat resuspend cells in an erlenmeyer flask, 1 h at 60°C (5.2 on dial). 
5. Centrifuge heated cells at 30,000 x g (19,500 rpm) for 6 min at 4°C. Decant and save 
supernatant. 
6. Filter supernatant through a 0.22 Ilm MillexGV (Millipore, Bedford, MA) syringe filter. 
7. Perform Bradford protein assay on filtered supernatant, store at -20°C until use. 
Coat plates: 
1. Adjust antigen concentration so that 
a. <ill (4) strains will be equally mixed in 0.1 M PBS 
b.4 Ilg protein per well/ divided equally between strains (1 Ilg each strain/well) 
c. 5 ml/plate or 50 Ill/well 
2. Add the adjusted mixed antigen to Immulon 4 plates (Dynatech, Chantilly, VA) 
3. Let plates stand overnight 4°C in humidor. 
4. Wash plates 3x in 0.1 M PBS 
5. Block plates with 100 III 1 % BSA in 0.1 M PBS, 30 min at 26°C (room temperature). 
6. Wash plates 3x in 0.1 M PBS, leave last PBS wash in wells until plates are used. 
Assay for optical density: 
1. In a separate dilution plate, add 120 III of diluent/well. 
2. Add 5 III of respective sera in triplicate to diluent wells. 
3. Empty PBS out of coated Immulon 4 plates. 
4. Mix sera and diluent 6 x in the wells of the dilution plates and transfer 50 III to coated 
plates using a multichannel pipettor, changing tips bewteen rows. 
5. Incubate plates at 37°C 1 h in humidor. 
6. Wash 3 x with 150 III wash buffer with 1 min incubations for each wash. 
7. Mix conjugate in diluent buffer 1 :2000, add 50 Ill/well. 
8. Incubate plates at 37°C 1 h in humidor. 
9. Wash 3 x with 150 III wash buffer with 1 min incubations for each wash. 
10. Add 30 III substrate to each well. 
11. Incubate 10 min at 26°C. 
12. Add 30 III stop solution. 
13. Read on advanced! program 8 - Dynatech MR7000 
Test wavelength = 450 nm 
Reference wavelength = 410 nm 
+ control SC pig = pig hypered with killed 3246pp 
- control = a known negative pig (culture) 
Blank = no serum 
Program 8 -pos = F 1 0-12 
neg = GI0-12 
blank = HlO-I2 
Program 11 - blank=F 1 0-12 
pos=GI0-12 
neg=HlO-12 
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Susceptibility Testing - Broth Microdilution Method 
Materials: The following are purchased from Sensititre: 
LB broth 
LB + 30% glycerol 
10 III sterile transfer loops cat. no.: E251586 
Mueller-Hinton broth tubes cat. no.: T3462 
1. autoclave glycerol 1 h 
2. cool 
3. add 30 ml to 70 ml LB 
4. mix well 
sterile dd H20 (5 ml) 
cryovials, 2 ml internal thread 
blood agar plates, 5% bovine or sheep blood 
1 III sterile inoculating loops 
cotton swabs 
Procedure: 
A. Isolating clones 
substrate strips 
dose heads 
micro titer plates 
1. Streak sample onto blood agar plates for isolation 
2. Incubate plates 37°C overnight 
3. Pick one well-isolated colony and streak onto new blood agar plate 
4. Incubate plates 37°C overnight 
B. Screening for resistance 
(calibrate nephlometer with each use) 
cat. no.: EI012 
cat. no.: E3010 
1. Set up a rack with 1 water tube and 1 Mueller-Hinton (M-H) tube for each isolate 
2. Add 1 substrate strip to each M-H tube for a minimum of 15 min prior to inoculation 
Note: Once substrate strips are added, broth must be used within 1 h. 
3. Pick 2-6 colonies from plate using sterile cotton tipped swab and inoculate water tube 
4. Vortex and adjust density according to nephlometer reading 
5. Transfer inoculum from water tube to M-H tube using 10 III loop 
6. Vortex and inoculate microtiter plate using auto diluter as per manufacturer's instructions 
7. Incubate plates 37°C for 18-20 h 
Note: do not stack plates more than 2 high 
8. Read plates after 18 h according to manufacturer's instructions. 
Note: do not read plates after 20 h. 
C. Freezing clones 
1. Label cryovials with appropriate information - study, isolate number, date inoculated. 
2. Add 1 ml LB + glycerol to cryovial 
3. Pick 4-8 colonies from last blood agar plate using sterile 1 III inoculating loops 
4. Shake loop in media to dislodge bacteria and screw cap tightly 
5. Freeze cryovials at -70°C 
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Susceptibility Testing - Disk Diffusion Method 
Materials: 
blood agar plates, 5% sheep or bovine blood 
Mueller-Hinton agar plates 
water tubes, 5 ml 
cotton swabs 
antibiotic disks (Difco) 
wooden sticks 
Procedure: 
1. Swab top of frozen clone and streak onto blood agar plate 
2. Incubate plates 37°C overnight 
3. Pick colonies from plate with swab and inoculate water tube 
4. Adjust density according to nephlometer 
5. Dip swab in tube to soak with inoculum 
6. Streak plate to achieve a confluent lawn, usually 3-4 times around plate 
7. Place disks on plate with autodispenser or forceps 
8. Press disks firmly and evenly to agar using wooden stick 
9. Incubate plates, agar side up, 37°C for 18-24 h 
10. Read using susceptibility testing sheets depending on antibiotic 
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